CAM
SCPH

ClariVest Asset Management’s scPharmaceuticals SCPH Stock Holding History

ClariVest Asset Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-80,784
Closed -$733K – 749
2023
Q1 		$733K Sell
80,784
-30,416
-27% -$223K 0.03% 323
2022
Q4 		$797K Buy
+111,200
New +$679K 0.04% 309

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClariVest Asset Management's SCPH Position: Q2 2023 in Review

ClariVest Asset Management sold out of scPharmaceuticals (SCPH) in Q2 2023, closing a stake of 80,784 shares — an estimated $733K sold.

ClariVest Asset Management first reported a position in SCPH in Q4 2022 and held it in 2 quarters. The position peaked at $797K in Q4 2022. 81 funds tracked by Wall St. Rank hold SCPH as of Q2 2023.

  • ClariVest Asset Management reported no remaining scPharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • ClariVest Asset Management sold 80,784 scPharmaceuticals shares in Q2 2023, an estimated $733K.
  • ClariVest Asset Management first reported a position in scPharmaceuticals in Q4 2022 and held it in 2 quarters.
  • ClariVest Asset Management's scPharmaceuticals position peaked at $797K in Q4 2022.
  • 81 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2023.

Based on ClariVest Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.